WHEL-C-109 · Strong evidence · 9/10

menopausal hormone therapy for menopause

Meta-analytic and umbrella-review evidence in postmenopausal women shows MHT effectively reduces vasomotor symptom frequency (RR 0.43) and severity (RR 0.29) and lowers fracture risk (RR 0.72), with additional cardiovascular benefit (improved FMD) when started within 10 years of menopause.

Origin · Existing drug · repurposing candidatePathway · 505(b)(2) · existing active ingredient, new indicationEvidence arm · Direct researchContradiction present

How to read thisThe summary above and the proposed mechanism are generated by the model from the sources it ingested, and are written as the model’s reasoning rather than established fact. Any figure quoted from MATRIX is a model-derived association score, not a clinical measurement. How far the published record backs this pair is carried by the score’s own rigor dimension and traced to verbatim sources at the foot of the page.

Hypothesized mechanism

Estrogen replacement improves endothelial function (increased flow-mediated arterial dilation) and counteracts estrogen-deficiency effects on thermoregulation and bone turnover.

This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.

How the score was reached, for this pair

The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 9 of 10 overall, a strong reading, from a direct rated strong in strength.

The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.

Direct research arm · anchors the headline9.0 / 10 · Strong

Scored for women. Evidence generated in women (female population, ~100% female). (band F1, ×1.00).

Corroboration

Evidence comes from multiple independent syntheses—an umbrella review (claims 13-19), a cardiovascular systematic review/meta-analysis (claims 2-12), and a clinical guidance source on menopause after cancer (claim 1)—all consistently supporting efficacy for vasomotor symptoms. The umbrella review pools many trials (e.g., 30 trials, 43,188 women for fracture) and converges with other sources, justifying a 2.

2 / 2

Rigor

The core evidence is from systematic reviews and meta-analyses/umbrella reviews of randomized trials (claims 2-19), with pooled RR and CI reporting. This represents high-rigor evidence design.

2 / 2

Specificity

Claims explicitly name menopausal hormone therapy (MHT) and menopause/postmenopausal women and menopausal symptoms (vasomotor symptoms, fracture, sexual function). Both intervention and condition are directly named.

2 / 2

Plausibility

The evidence supports mechanism: MHT improves flow-mediated arterial dilation (FMD, SMD 1.46) as an endothelial vasodilatory measure, and directly addresses estrogen-deficiency menopausal symptoms. The FMD finding provides evidenced (not merely asserted) mechanistic support for vascular benefit.

2 / 2

Consistency

Multiple sources agree on direction for vasomotor symptom benefit (claims 1, 13, 14) and fracture (claims 15, 17, 18), and the FMD benefit is consistently reported (claims 2, 7, 12). Some nuance exists (no NMD improvement, all-cause death benefit only with early initiation), but the efficacy results align in direction across sources.

1 / 2

How the scoring rubric works, in general →

Layers not covered for this pair

Sex-specific pharmacokineticsNone on file

Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.

More on the sex-specific pharmacokinetics layer and its sources →

Cycle-phase dependenceNone on file

Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.

More on the cycle-phase layer and its sources →

Source evidence · what the pipeline ingested

These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).

Every source below belongs to this signal’s evidence arm, Direct research. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.

1seems to be safe for many patients with cancer PubMed · PMID 38458217 ↗
2no significant difference between MHT and placebo (or no treatment) in all-cause death (RR = 0.96, 95%CI 0.85 to 1.09, I2 = 14%) PubMed · PMID 38263123 ↗
3no significant difference between MHT and placebo (or no treatment) in all-cause death (RR = 0.96, 95%CI 0.85 to 1.09, I2 = 14%) and cardiovascular events (RR = 0.97, 95%CI 0.82 to 1.14, I2 = 38%) in the overall population of postmenopausal women PubMed · PMID 38263123 ↗
4increases the risk of stroke PubMed · PMID 38263123 ↗

These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.

The primary sources and pipelines this evidence is drawn from →

← Back to the full index